Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -35

Boston Scientific misses 2026 guidance as Boston Scientific stock faces a reset

Guidance lowered Operational disruption AI-generated analysis

πŸ“‰ Boston Scientific missed its third-quarter and full-year 2026 sales and adjusted earnings guidance due to a cybersecurity incident disrupting manufacturing and shipments.

πŸ’° Second-quarter 2026 net sales reached USD 5.44 billion, up 7.5% year over year, with diluted EPS of USD 0.61 and an operating margin of 22.0%.

πŸ”’ A major cyberattack on September 8 disrupted operations for eight days, affecting order processing and supply execution timing across global facilities.

πŸ“Š Oppenheimer analyst Suraj Kalia cut the price target from USD 85 to USD 65 while maintaining an Outperform rating due to the disruption and competition.

πŸ₯ WATCHMAN global sales grew 4.2% organically in Q2 2026, demonstrating resilience in the left atrial appendage closure segment despite broader challenges.

⚑ Electrophysiology revenue grew 9.1% organically in Q2 2026, showing strong performance in a key growth area for the medical device company.

πŸ“… The company plans to release an updated operational and financial outlook with third-quarter results on October 28, 2026.

🏭 Major distribution centers processed orders at normal levels while sterilization facilities remained operational during the recovery phase.

πŸ“‰ Stock price stood at USD 43.65 on September 30, 2026, trading USD 1.45 above the 52-week low of USD 42.20.

πŸ’Ό Boston Scientific maintains a market capitalization of USD 64.9 billion as it navigates the operational reset following the security breach.

Bullish Signals
  • Second-quarter 2026 net sales reached USD 5.44 billion, representing a 7.5% year-over-year increase that establishes a strong operational base.
  • Diluted earnings per share of USD 0.61 and an operating margin of 22.0% in Q2 2026 demonstrate robust underlying profitability.
  • WATCHMAN global sales grew 4.2% organically in fiscal second-quarter 2026, indicating resilience in a key product line.
  • Electrophysiology revenue achieved 9.1% organic growth in Q2 2026, highlighting strength in a strategic high-growth segment.
  • Major distribution centers and sterilization facilities remained operational at or above normal levels during the recovery period.
Risk Factors
  • The company missed its third-quarter and full-year 2026 sales and adjusted earnings guidance following a significant cybersecurity incident.
  • An eight-day disruption to manufacturing, order processing, and shipments forced a reset of operational expectations for fiscal 2026.
  • Oppenheimer analyst Suraj Kalia cut the price target from USD 85 to USD 65 citing the cyber disruption and competitive pressures.
  • The cybersecurity incident disrupted supply execution and the timing of customer orders, potentially affecting earnings leverage.
  • Boston Scientific must now prove that operational recovery can protect its underlying growth profile after the security breach.
Full Analysis
Boston Scientific Corp. faces significant pressure to meet its fiscal 2026 guidance following a major cybersecurity incident that disrupted manufacturing, order processing, and shipments in late September 2026. The company had previously projected adjusted earnings between USD 3.28 and 3.32 per share for the full year, with third-quarter expectations of USD 0.80 to 0.82 per share. Reuters reported on September 8 that these targets were no longer expected to be met as the firm works through operational recovery. Despite the cyber disruption, Boston Scientific reported robust second-quarter financial performance in Q2 2026, posting net sales of USD 5.44 billion, representing a 7.5% year-over-year increase. Diluted earnings per share reached USD 0.61 with an operating margin of 22.0%, establishing a strong operational base that the company must defend in its upcoming October 28 results. Major distribution centers and sterilization facilities remained largely functional, though supply execution timing was affected. Analyst sentiment has turned cautious as Oppenheimer lowered its price target from USD 85 to USD 65 while maintaining an Outperform rating, citing the eight-day disruption and competitive pressures in left atrial appendage closure and electrophysiology. However, specific product lines showed resilience with WATCHMAN global sales growing 4.2% organically and electrophysiology revenue up 9.1%. The stock traded at USD 43.65 on September 30, reflecting a market reset as investors assess the long-term impact of the security breach on growth profiles. Management plans to provide an updated operational and financial outlook with third-quarter results scheduled for release on October 28, 2026. The event serves as a critical inflection point where Boston Scientific must demonstrate that its underlying growth trajectory can withstand such disruptions. With a market capitalization of USD 64.9 billion, the company's ability to normalize operations quickly will be closely watched by investors evaluating its resilience against cyber threats and competitive headwinds.